Liquidia Stock Price

-0.08 (-3.07%)


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Liquidia Corporation LQDA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.08 -3.07% 2.53 18:00:03
Open Price Low Price High Price Close Price Prev Close
2.63 2.47 2.67 2.53 2.61
Bid Price Ask Price Spread News
2.52 2.56 0.04 1 -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,061 691,715 $ 2.52 $ 1,740,637 430,616 2.34 - 12.10
Last Trade Time Type Quantity Stock Price Currency
17:32:09 10 $ 2.56 USD

Liquidia Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 131.49M 51.97M 28.61M $ 739.63k $ - -1.79 -1.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 441.51k 1.20%

more financials information »

Liquidia News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical LQDA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.752.782.472.65394,817-0.22-8.0%
1 Month2.953.242.472.86413,222-0.42-14.24%
3 Months2.523.242.352.75493,6890.010.4%
6 Months3.083.852.342.94946,947-0.55-17.86%
1 Year10.2112.102.343.62853,168-7.68-75.22%
3 Years12.4538.462.344.65368,766-9.92-79.68%
5 Years12.4538.462.344.65368,766-9.92-79.68%

Liquidia Description

Liquidia Corp, formerly Liquidia Technologies Inc is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.